Amylyx Advances AMX0318 as New Rare-Disease Candidate

Amylyx Pharmaceuticals Inc ( (AMLX) ) has shared an update.

On January 8, 2026, Amylyx Pharmaceuticals selected AMX0318, a long-acting GLP-1 receptor antagonist discovered under its collaboration with peptide drug specialist Gubra A/S, as a development candidate for post-bariatric hypoglycemia and other rare diseases, triggering a $4 million milestone payment and positioning Gubra to earn more than $50 million in additional development and commercialization milestones plus mid-single-digit royalties on worldwide sales. The company also updated its corporate presentation in January 2026 to highlight a growing rare-disease pipeline led by avexitide, which is in a Phase 3 LUCIDITY trial for PBH with topline data expected in the third quarter of 2026 and a potential 2027 launch, while earlier clinical data have shown avexitide can sharply reduce hypoglycemic events in PBH patients, underscoring Amylyx’s strategic push to build a leading franchise in GLP-1 pathway modulation for underserved endocrine and neurodegenerative indications.

The most recent analyst rating on (AMLX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Amylyx Pharmaceuticals Inc stock, see the AMLX Stock Forecast page.

Spark’s Take on AMLX Stock

According to Spark, TipRanks’ AI Analyst, AMLX is a Neutral.

Amylyx Pharmaceuticals’ overall stock score is primarily impacted by its financial challenges, including declining revenues and operational losses. The technical analysis shows some short-term bullish momentum, but the valuation remains unattractive due to negative earnings. The earnings call provides a positive outlook with a strong cash position and progress in drug development, although delays in key trials present risks.

To see Spark’s full report on AMLX stock, click here.

More about Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals Inc. is a biopharmaceutical company focused on developing novel therapies for diseases with high unmet medical needs, particularly serious and fatal neurodegenerative diseases and endocrine conditions such as post-bariatric hypoglycemia (PBH), congenital hyperinsulinism, Wolfram syndrome, and amyotrophic lateral sclerosis. Its pipeline includes avexitide, a first-in-class inhibitor of GLP-1 receptor activity with FDA Breakthrough and Orphan Drug Designations for hyperinsulinemic hypoglycemia, AMX0035 for Wolfram syndrome, AMX0114 for ALS, and the newly advanced AMX0318, a long-acting GLP-1 receptor antagonist targeting PBH and other rare diseases.

Average Trading Volume: 1,577,356

Technical Sentiment Signal: Buy

Current Market Cap: $1.25B

See more data about AMLX stock on TipRanks’ Stock Analysis page.